β-arrestin2 regulates TRAIL-induced HepG2 cell apoptosis via the Src-extracellular signal-regulated signaling pathway

Qi,Zhilin; Qi,Shimei; Gui,Lin; Shen,Lei

doi:10.3892/mmr.2016.5216

β-arrestin2 regulates TRAIL-induced HepG2 cell apoptosis via the Src-extracellular signal-regulated signaling pathway

Authors:
- Zhilin Qi
- Shimei Qi
- Lin Gui
- Lei Shen
View Affiliations

Affiliations: Department of Biochemistry, Wannan Medical College, Wuhu, Anhui 241002, P.R. China, Department of Microbiology and Immunology, Wannan Medical College, Wuhu, Anhui 241002, P.R. China, Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Science, Nanjing Normal University, Nanjing, Jiangsu 210023, P.R. China
Published online on: May 6, 2016 https://doi.org/10.3892/mmr.2016.5216
Pages: 263-270

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

β-arrestins, including β-arrestin1 and β‑arrestin2, two ubiquitously expressed members of the arrestin family in various types of tissue, are adaptor proteins that modulate the desensitization and trafficking of seven membrane‑spanning receptors. Recently, β‑arrestins have been shown to bind to numerous signaling molecules, including c‑Src and mitogen‑activated protein kinase family members. In addition, accumulating evidence has suggested that β‑arrestins are involved in the anti‑apoptosis signaling pathway by associating with kinases, such as Akt and ERK, and altering their activities. However, the role of β‑arrestins in tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL)‑induced apoptosis remains unclear. In the present study, β‑arrestin2, but not β‑arrestin1, was observed to modulate TRAIL‑triggered HepG2 cell apoptosis by regulating activation of the Src‑extracellular signal‑regulated kinase (ERK) signaling pathway. Using overexpression and RNA interference experiments, β‑arrestin2 was demonstrated to prevent TRAIL‑induced HepG2 cell apoptosis. Additionally, β‑arrestin2 exerted an additive effect on TRAIL‑induced activation of Src and ERK. Furthermore, downregulating β‑arrestin2 expression attenuated the TRAIL‑induced activation of Src and ERK survival signaling and enhanced TRAIL‑induced apoptosis. PP2, a pharmacological inhibitor of Src, reduced activation of the Src‑ERK signaling pathway and enhanced TRAIL‑induced HepG2 cell apoptosis. Co-immunoprecipitation experiments demonstrated a physical association between β‑arrestin2 and Src, and TRAIL stimulation resulted in enhanced quantities of the β‑arrestin2/Src complex. A notable interaction was identified between β‑arrestin2 and death receptors (DR)4 and 5, but only in the presence of TRAIL stimulation. To the best of our knowledge, these findings are the first to demonstrate that β‑arrestin2 mediates TRAIL‑induced apoptosis by combing with DRs and Src, and regulates the activation of Src‑ERK signaling in HepG2 cells. It is hypothesized that the formation of a signaling complex comprising DR, β‑arrestin2 and Src is required for the action of TRAIL on HepG2 cell apoptosis, which provides a novel insight into analyzing the effects of β‑arrestin2 on protecting cells from TRAIL‑induced apoptosis.

View Figures

View References

1	Shenoy SK and Lefkowitz RJ: β-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci. 32:521–533. 2011. View Article : Google Scholar : PubMed/NCBI
2	Violin JD and Lefkowitz RJ: Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci. 28:416–422. 2007. View Article : Google Scholar : PubMed/NCBI
3	DeFea KA: Beta-arrestins as regulators of signal termination and transduction: How do they determine what to scaffold? Cellular signalling. 23:621–629. 2011. View Article : Google Scholar
4	Yang X, Zhou G, Ren T, Li H, Zhang Y, Yin D, Qian H and Li Q: β-Arrestin prevents cell apoptosis through pro-apoptotic ERK1/2 and p38 MAPKs and anti-apoptotic Akt pathways. Apoptosis. 17:1019–1026. 2012. View Article : Google Scholar : PubMed/NCBI
5	Zhang Z, Hao J, Zhao Z, Ben P, Fang F, Shi L, Gao Y, Liu J, Wen C, Luo L and Yin Z: Beta-Arrestins facilitate ubiquitin-dependent degradation of apoptosis signal-regulating kinase 1 (ASK1) and attenuate H O 2009. 2 2-induced apoptosis. Cell Signal. 21:1195–1206
6	Wang Y, Tang Y, Teng L, Wu Y, Zhao X and Pei G: Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol. 7:139–147. 2006. View Article : Google Scholar
7	Hu S, Wang D, Wu J, Jin J, Wei W and Sun W: Involvement of β-arrestins in cancer progression. Mol Biol Rep. 40:1065–1071. 2013. View Article : Google Scholar
8	Ahn S, Kim J, Hara MR, Ren XR and Lefkowitz RJ: {beta}-Arrestin-2 mediates anti-apoptotic signaling through regulation of BAD phosphorylation. J Biol Chem. 284:8855–8865. 2009. View Article : Google Scholar : PubMed/NCBI
9	Sun X, Zhang Y, Wang J, Wei L, Li H, Hanley G, Zhao M, Li Y and Yin D: Beta-arrestin 2 modulates resveratrol-induced apoptosis and regulation of Akt/GSK3β pathways. Biochim Biophys Acta. 1800:912–918. 2010. View Article : Google Scholar : PubMed/NCBI
10	Wu GS: TRAIL as a target in anti-cancer therapy. Cancer Lett. 285:1–5. 2009. View Article : Google Scholar : PubMed/NCBI
11	Moon DO, Park SY, Choi YH, Ahn JS and Kim GY: Guggulsterone sensitizes hepatoma cells to TRAIL-induced apoptosis through the induction of CHOP-dependent DR5: Involvement of ROS-dependent ER-stress. Biochem Pharmacol. 82:1641–1650. 2011. View Article : Google Scholar : PubMed/NCBI
12	Guo SY, Liu SG, Liu L, Zhou XJ and Gu Y: RNAi silencing of the MEKK3 gene promotes TRAIL-induced apoptosis in MCF-7 cells and suppresses the transcriptional activity of NF-κB. Oncol Rep. 27:441–446. 2012.
13	Falschlehner C, Emmerich CH, Gerlach B and Walczak H: TRAIL signalling: Decisions between life and death. Int J Biochem Cell Biol. 39:1462–1475. 2007. View Article : Google Scholar : PubMed/NCBI
14	LeBlanc HN and Ashkenazi A: Apo2 L/TRAIL and its death and decoy receptors. Cell Death Differ. 10:66–75. 2003. View Article : Google Scholar : PubMed/NCBI
15	Álvarez CJ, Lodeiro M, Theodoropoulou M, Camiña JP, Casanueva FF and Pazos Y: Obestatin stimulates Akt signalling in gastric cancer cells through beta-arrestin-mediated epidermal growth factor receptor transactivation. Endocr Relat Cancer. 16:599–611. 2009. View Article : Google Scholar : PubMed/NCBI
16	Im SR and Jang YJ: Aspirin enhances TRAIL-induced apoptosis via regulation of ERK1/2 activation in human cervical cancer cells. Biochem Biophys Res Commun. 424:65–70. 2012. View Article : Google Scholar : PubMed/NCBI
17	Zhao J, Lu Y and Shen HM: Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells. Cancer Lett. 314:8–23. 2012. View Article : Google Scholar
18	Qi S, Xin Y, Qi Z, Xu Y, Diao Y, Lan L, Luo L and Yin Z: HSP27 phosphorylation modulates TRAIL-induced activation of Src-Akt/ERK signaling through interaction with β-arrestin2. Cell Signal. 26:594–602. 2014. View Article : Google Scholar
19	Bareford MD, Hamed HA, Allegood J, Cruickshanks N, Poklepovic A, Park MA, Ogretmen B, Spiegel S, Grant S and Dent P: Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling. Cancer Biol Ther. 13:793–803. 2012. View Article : Google Scholar : PubMed/NCBI
20	Park EJ, Chung HJ, Park HJ, Kim GD, Ahn YH and Lee SK: Suppression of Src/ERK and GSK-3/β-catenin signaling by pinosylvin inhibits the growth of human colorectal cancer cells. Food Chem Toxicol. 55:424–433. 2013. View Article : Google Scholar : PubMed/NCBI
21	Pierce KL and Lefkowitz RJ: Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. Nat Rev Neurosci. 2:727–733. 2001. View Article : Google Scholar : PubMed/NCBI
22	Kook S, Gurevich VV and Gurevich EV: Arrestins in apoptosis. Arrestins-Pharmacology and Therapeutic Potential. Gurevich VV: 219. 1st edition. Springer-Verlag; Berlin, Heidelberg: pp. 309–339. 2014, View Article : Google Scholar
23	Maksimovic-Ivanic D, Stosic-Grujicic S, Nicoletti F and Mijatovic S: Resistance to TRAIL and how to surmount it. Immunol Res. 52:157–168. 2012. View Article : Google Scholar : PubMed/NCBI
24	Kim SR, Jung YR, Kim DH, An HJ, Kim MK, Kim ND and Chung HY: Caffeic acid regulates LPS-induced NF-κB activation through NIK/IKK and c-Src/ERK signaling pathways in endothelial cells. Arch Pharm Res. 37:539–547. 2014. View Article : Google Scholar
25	Kim JI, Lakshmikanthan V, Frilot N and Daaka Y: Prostaglandin E2 promotes lung cancer cell migration via EP4-βArrestin1-c-Src signalsome. Mol Cancer Res. 8:569–577. 2010. View Article : Google Scholar : PubMed/NCBI
26	Dasgupta P, Rizwani W, Pillai S, Davis R, Banerjee S, Hug K, Lloyd M, Coppola D, Haura E and Chellappan SP: ARRB1-mediated regulation of E2F target genes in nicotine-induced growth of lung tumors. J Natl Cancer Inst. 103:317–333. 2011. View Article : Google Scholar : PubMed/NCBI
27	Kook S, Zhan X, Cleghorn WM, Benovic JL, Gurevich VV and Gurevich EV: Caspase-cleaved arrestin-2 and BID cooperatively facilitate cytochrome C release and cell death. Cell Death Differ. 21:172–184. 2014. View Article : Google Scholar
28	Lodeiro M, Theodoropoulou M, Pardo M, Casanueva FF and Camiña JP: C-Src regulates Akt signaling in response to ghrelin via beta-arrestin signaling-independent and-dependent mechanisms. PLoS One. 4:e46862009. View Article : Google Scholar
29	Marchese A, Chen C, Kim YM and Benovic JL: The ins and outs of G protein-coupled receptor trafficking. Trends Biochem Sci. 28:369–376. 2003. View Article : Google Scholar : PubMed/NCBI
30	Laporte SA, Oakley RH, Holt JA, Barak LS and Caron MG: The interaction of beta-arrestin with the AP-2 adaptor is required for the clustering of beta 2-adrenergic receptor into clathrin-coated pits. J Biol Chem. 275:23120–23126. 2000. View Article : Google Scholar : PubMed/NCBI
31	Prossnitz ER: Novel roles for arrestins in the post-endocytic trafficking of G protein-coupled receptors. Life Sci. 75:893–899. 2004. View Article : Google Scholar : PubMed/NCBI